Long-term fluoxetine administration does not result in major changes in bone architecture and strength in growing rats

Journal of Cellular Biochemistry

Volumn 101, Issue 2, 2007, Pages 360-368

  Westbroek, I ^a,c   Waarsing, J H ^c   Van Leeuwen, J P T M ^c   Waldum, H ^b   Reseland, J E ^d   Weinans, H ^c   Syversen, U ^a,b   Gustafsson, B I ^a,b  

^a NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

^b TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

^c ERASMUS MEDICAL CENTER   (Netherlands)

^d UNIVERSITY OF OSLO   (Norway)

Author keywords

BMD; Bone architecture; Bone quality; Fluoxetine; Micro CT; Serotonin

Indexed keywords

ADIPONECTIN; FLUOXETINE; LEPTIN; SEROTONIN UPTAKE INHIBITOR;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BODY FAT; BODY WEIGHT; BONE DEVELOPMENT; BONE METABOLISM; BONE STRENGTH; BONE TISSUE; CONTROLLED STUDY; FEMALE; FEMUR; FOLLOW UP; LONG TERM CARE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RAT; SEROTONINERGIC SYSTEM; TREATMENT DURATION;

ADIPONECTIN; ANIMALS; BONE AND BONES; BONE DENSITY; CHILD; FEMALE; FLUOXETINE; HUMANS; LEPTIN; RATS; RATS, SPRAGUE-DAWLEY; SEROTONIN UPTAKE INHIBITORS; STRESS, MECHANICAL;

ANIMALIA; RATTUS;

EID: 34247857437     PISSN: 07302312     EISSN: 10974644     Source Type: Journal    
DOI: 10.1002/jcb.21177     Document Type: Article

References (32)

1. Battaglino R, Fu J, Spate U, Ersoy U, Joe M, Sedaghat L, Stashenko P. 2004. Serotonin regulates osteoclast differentiation through its transporter. J Bone Miner Res 19:1420-1431.
2. Bliziotes MM, Eshleman AJ, Zhang XW, Wiren KM. 2001. Neurotransmitter action in osteoblasts: Expression of a functional system for serotonin receptor activation and reuptake. Bone 29:477-486.
3. Bolo NR, Hode Y, Macher JP. 2004. Long-term sequestration of fluorinated compounds in tissues after fluvoxamine or fluoxetine treatment: A fluorine magnetic resonance spectroscopy study in vivo. Magma 16:268-276.
4. Cole AA, Walters LM. 1987. Tartrate-resistant acid phosphatase in bone and cartilage following decalcification and cold-embedding in plastic. J Histochem Cytochem 35:203-206.
5. Dryden S, Frankish HM, Wang Q, Pickavance L, Williams G. 1996. The serotonergic agent fluoxetine reduces neuropeptide Y levels and neuropeptide Y secretion in the hypothalamus of lean and obese rats. Neuroscience 72:557-566.
6. Ducy P, Amling M, Takeda S, Priemel M, Schilling AF, Beil FT, Shen J, Vinson C, Rueger JM, Karsenty G. 2000. Leptin inhibits bone formation through a hypothalamic relay: A central control of bone mass. Cell 100:197-207.
7. Fava M, Judge R, Hoog SL, Nilsson ME, Koke SC. 2000. Fluoxetine versus sertraline and paroxetine in major depressive disorder: Changes in weight with long-term treatment. J Clin Psychiatry 61:863-867.
8. Frishman WH, Huberfeld S, Okin S, Wang YH, Kumar A, Shareef B. 1995. Serotonin and serotonin antagonism in cardiovascular and non-cardiovascular disease. J Clin Pharmacol 35:541-572.
9. Gershon MD. 1999. Review article: Roles played by 5-hydroxytryptamine in the physiology of the bowel. Aliment Pharmacol Ther 13(Suppl 2):15-30.
10. Gordeladze JO, Reseland JE. 2003. A unified model for the action of leptin on bone turnover. J Cell Biochem 88:706-712.
11. Gustafsson BI, Westbroek I, Waarsing JH, Waldum H, Solligard E, Brunsvik A, Dimmen S, van Leeuwen JP, Weinans H, Syversen U. 2006a. Long-term serotonin administration leads to higher bone mineral density, affects bone architecture, and leads to higher femoral bone stiffness in rats. J Cell Biochem 97:1283-1291.
12. Gustafsson BI, Thommesen L, Stunes AK, Tommeras K, Westbroek I, Waldum HL, Slordahl K, Tamburstuen MV, Reseland JE, Syversen U. 2006b. Serotonin and fluoxetine modulate bone cell function in vitro. J Cell Biochem 98:139-151.
13. Hildebrand T, Ruegsegger P. 1997a. Quantification of bone microarchitecture with the structure model index. Comput Methods Biomech Biomed Eng 1:15-23.
14. Hildebrand T, Ruegsegger P. 1997b. A new method for the model-independent assessment of thickness in three-dimensional images. J Microsc 185:67-75.
15. Hsiao SH, Chung HH, Tong YC, Cheng JT. 2006. Chronic fluoxetine administration desensitizes the hyperglycemia but not the anorexia induced by serotonin in rats receiving fructose-enriched chow. Neurosci Lett 404:6-8.
16. Koch S, Perry KW, Nelson DL, Conway RG, Threlkeld PG, Bymaster FP. 2002. R-fluoxetine increases extracellular DA, NE, as well as 5-HT in rat prefrontal cortex and hypothalamus: An in vivo microdialysis and receptor binding study. Neuropsychopharmacology 27:949-959.
17. Luo XH, Guo LJ, Yuan LQ, Xie H, Zhou HD, Wu XP, Liao EY. 2005. Adiponectin stimulates human osteoblasts proliferation and differentiation via the MAPK signaling pathway. Exp Cell Res 309:99-109.
18. Moiseiwitsch JR. 2000. The role of serotonin and neurotransmitters during craniofacial development. Crit Rev Oral Biol Med 11:230-239.
19. Moosa MY, Panz VR, Jeenah FY, Joffe BI. 2003. African women with depression: The effect of imipramine and fluoxetine on body mass index and leptin secretion. J Clin Psychopharmacol 23:549-552.
20. Ni YG, Miledi R. 1997. Blockage of 5HT2C serotonin receptors by fluoxetine (Prozac). Proc Natl Acad Sci USA 94:2036-2040.
21. Odgaard A, Gundersen HJ. 1993. Quantification of connectivity in cancellous bone, with special emphasis on 3-D reconstructions. Bone 14:173-182.
22. Oshima K, Nampei A, Matsuda M, Iwaki M, Fukuhara A, Hashimoto J, Yoshikawa H, Shimomura I. 2005. Adiponectin increases bone mass by suppressing osteoclast and activating osteoblast. Biochem Biophys Res Commun 331:520-526.
23. Palvimaki EP, Roth BL, Majasuo H, Laakso A, Kuoppamaki M, Syvalahti E, Hietala J. 1996. Interactions of selective serotonin reuptake inhibitors with the serotonin 5-HT2c receptor. Psychopharmacology (Berl) 126:234-240.
24. Takeda S, Elefteriou F, Levasseur R, Liu X, Zhao L, Parker KL, Armstrong D, Ducy P, Karsenty G. 2002. Leptin regulates bone formation via the sympathetic nervous system. Cell 111:305-317.
25. Turner CH, Burr DB. 1993. Basic biomechanical measurements of bone: A tutorial. Bone 14:595-608.
26. Warden SJ, Robling AG, Sanders MS, Bliziotes MM, Turner CH. 2005. Inhibition of the serotonin (5-hydroxytryptamine) transporter reduces bone accrual during growth. Endocrinology 146:685-693.
27. Weintrob N, Cohen D, Klipper-Aurbach Y, Zadik Z, Dickerman Z. 2002. Decreased growth during therapy with selective serotonin reuptake inhibitors. Arch Pediatr Adolesc Med 156:696-701.
28. Westbroek I, van der Plas A, de Rooij KE, Klein-Nulend J, Nijweide PJ. 2001. Expression of serotonin receptors in bone. J Biol Chem 276:28961-28968.
29. Wong DT, Reid LR, Threlkeld PG. 1988. Suppression of food intake in rats by fluoxetine: Comparison of enantiomers and effects of serotonin antagonists. Pharmacol Biochem Behav 31:475-479.
30. Yamada J, Sugimoto Y, Ujikawa M. 1999. The serotonin precursor 5-hydroxytryptophan elevates serum leptin levels in mice. Eur J Pharmacol 383:49-51.
31. Yamada J, Ujikawa M, Sugimoto Y. 2000. Serum leptin levels after central and systemic injection of a serotonin precursor, 5-hydroxytryptophan, in mice. Eur J Pharmacol 406:159-162.
32. Yamakawa J, Takahashi T, Itoh T, Kusaka K, Kawaura K, Wang XQ, Kanda T. 2003. A novel serotonin blocker, sarpogrelate, increases circulating adiponectin levels in diabetic patients with arteriosclerosis obliterans. Diabetes Care 26:2477-2478.